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Abstract
Glioblastoma is the most malignant and lethal form of astrocytoma, with patients having a median survival time of
approximately 15 months with current therapeutic modalities. It is therefore important to identify novel therapeutics. There
is mounting evidence that microglia (specialized brain-resident macrophages) play a significant role in the development
and progression of glioblastoma tumors. In this paper we show that microglia, in addition to stimulating glioblastoma cell
invasion, also promote glioblastoma cell proliferation and resistance to ionizing radiation in vitro. We found that
semapimod, a drug that selectively interferes with the function of macrophages and microglia, potently inhibits microglia-
stimulated GL261 invasion, without affecting serum-stimulated glioblastoma cell invasion. Semapimod also inhibits
microglia-stimulated resistance of glioblastoma cells to radiation, but has no significant effect on microglia-stimulated
glioblastoma cell proliferation. We also found that intracranially administered semapimod strongly increases the survival of
GL261 tumor-bearing animals in combination with radiation, but has no significant benefit in the absence of radiation. In
conclusion, our observations indicate that semapimod sensitizes glioblastoma tumors to ionizing radiation by targeting
microglia and/or infiltrating macrophages.
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Introduction
Glioblastoma Multiforme (GBM) is the most malignant and
lethal form of astrocytoma (WHO grade IV). Despite recent
advancements in the standards of care, the outlook for GBM
patients remains bleak and new therapies are therefore swiftly
required. Currently, the standard of care is gross tumor resection
followed by radiation treatment and concurrent chemotherapy
[1]. However, even after extensive therapy, relapse is certain and
the disease remains lethal, with a life expectancy of little over one
year after diagnosis [2].
Microglia are the resident macrophages of the central
nervous system (CNS) [3,4]. They are glial cells that are of
hematopoietic origin. Microglia are the main phagocytic and
immunocompetent cells in the CNS. They are activated by
damage or infection and phagocytose debris and other cells.
They also present antigens and secrete cytokines that regulate
inflammatory responses. Microglia are attracted by glial
tumors via multiple tumor-secreted factors and are enriched
in the tumor periphery [5,6,7]. The extent of microglia
infiltration correlates with tumor grade [8,9]. In glioblastoma,
microglia account for as much as 30% of the tumor mass [10].
Instead of producing an anti-tumor effect, microglia are co-
opted by the tumor to favor its growth [5,6,7]. In this
reprogrammed state, they support the tumor by secreting
factors that promote immunosuppression, and glioblastoma
cell proliferation, invasion and angiogenesis. Importantly,
selective ablation of microglia has been shown to inhibit
glioblastoma invasiveness and growth [11,12].
Semapimod (initially termed CNI-1493) is a multivalent
guanylhydrazone small molecule that was developed as a
targeted inhibitor of cytokine-inducible L-arginine transport in
macrophages [13,14]. Remarkably, no significant effect of
semapimod on cells from other lineages has been noted [15].
Semapimod has been shown to have significant efficacy in
several animal models of inflammation, including lethal sepsis
[16]. Importantly, semapimod has already been tested in a
phase II clinical trial for Crohn’s disease and was shown to be
very well tolerated in humans [17]. In this study, we examined
whether semapimod can blunt the stimulatory effect of
microglia on the malignant behavior of glioblastoma cells,
both in vitro and in a syngeneic orthotopic mouse model of
glioblastoma.
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Materials and Methods
Ethics Statement
All procedures involving mice were conducted in accordance
with the National Institutes of Health regulations and ARRIVE
guidelines concerning the use and care of experimental animals.
The study of mice was approved by the Institutional Animal Care
and Use Committee (IACUC) of the Feinstein Institute. All
surgeries were performed under isoflurane anesthesia, and all
efforts were made to minimize suffering.
Cell Culture
Murine GL261 glioblastoma cells were obtained from the
National Cancer Institute (Frederick, MD, USA) and normal
murine microglia, isolated from C57Bl/6 mice [18], were obtained
from S. Coniglio (Albert Einstein College of Medicine) [19]. Both
cultures were maintained in Macrophage Serum-Free Medium
(MSFM; Life Technologies Corporation) with 10% fetal calf
serum. Microglia were supplemented with 10 ng/mL recombinant
mouse granulocyte macrophage–colony-stimulating factor (GM-
CSF) (R&D Systems). All cultures were grown at 37uC in a
humidified atmosphere of 5% CO2, 95% air. Cell lines were tested
for the presence of contaminating mycoplasma during experi-
mentation.
Reagents
Semapimod was produced in house by Dr. Yousef Al-Abed and
prepared as a stock concentration of 20 mM in 7% DMSO and
ddH20. It was diluted for experiments using Dulbecco’s phos-
phate-buffered saline (PBS) to concentrations required.
Invasion Assays
Glioblastoma and microglial cells were labelled with cell tracker
green CMFDA and with cell tracker red CMTPX, respectively,
and then embedded in 50 mL of 10 mg/mL basement membrane
extract (BME) (Trevigen). The mixture was then placed in a
transwell insert (previously coated with 1 mg/mL fibronectin on
the bottom side of the 8 mm filter to maintain adhesion of the cells
that invaded through the filter) and allowed to polymerize for
30 min at 37uC. Subsequently, serum free medium was added to
both wells. To maintain constant cell numbers, cells were plated at
a density per invasion chamber of 156104 GL261 cells and 56104
microglia cells in MSFM. Semapimod or its diluent was added at
varying concentrations into the BME and in the media above and
below the transwell. Invasion chambers were incubated for 48 h
and subsequently fixed in 3.7% formaldehyde in phosphate-
buffered saline (PBS). The gel in the transwell inserts was carefully
removed. Invaded glioblastoma cells were imaged with a Zeiss
Axiovision inverted microscope and a 106 objective. All invaded
cells were counted.
To measure the invasion of microglia toward glioblastoma cells
in vitro, we used a variant of the glioblastoma cell invasion assay.
First, 156104 Gl261 cells were plated in MSFM medium
overnight and subsequently were placed in serum free medium.
Subsequently, 56104 microglia cells were embedded in 50 mL of
10 mg/mL BME with or without 200 nM semapimod, placed in a
8 mm transwell (previously coated with 1 mg/mL fibronectin on
the bottom side of the 8 mm filter to maintain adhesion of the cells
that invaded through the filter) and allowed to polymerize for
30 min at 37uC. The transwell chambers were then placed above
the previously plated GL261. After 48 h of incubation, the
chambers were fixed in 3.7% formaldehyde in PBS. The cells were
stained with 0.2% crystal violet in 2% ethanol. The remaining
BME was carefully removed and the inserts were allowed to dry.
Cells attached to the bottom of the filter were imaged as for the
invasion assay and the total number of invaded microglia was
determined.
Colony Formation Assay
Gl261 cells and microglia were labeled as described for the
invasion assay and were co-cultured in serum overnight and then
changed to serum free medium for 48 h in the absence of serum at
a 1:1 ratio at a density of 56105 per well of a 6-well plate in the
presence or absence of 200 nM semapimod. Subsequently, cells
were subjected to 3 Gy of X-ray irradiation using a Radionics
160 kV irradiator. Two days after irradiation, cells were trypsin-
ized, counted using a fluorescence microscope and 500 GL261
cells were plated in 6 cm dishes containing 10% FBS MSFM
medium. Colony formation was allowed to proceed for 12 days,
with medium changes every other day. Subsequently, the cells
were fixed in 3.7% formaldehyde in PBS and stained with 0.2%
(w/v) sulpharhodamine B (SRB) dye in 1% acetic acid for 20 min.
The dishes were washed with 1% glacial acetic acid and allowed to
dry. Plates were scanned and processed using Photoshop 5
(Adobe). Images were changed to grayscale and background
threshold intensity was set. Colonies were counted automatically
by Image J (rsbweb.nih.gov/ij/) and the numbers graphed.
Proliferation Assay
50,000 GL261 cells were cultured overnight in the absence or
presence or microglia (50,000 or 150,000) in serum-containing
medium and subsequently cultured in the presence or absence of
200 nM semapimod in a 6-well dish in serum-free conditions.
Microglia were added in a ratio of 1:1 or 1:3 GL261:microglia.
After 72 h of incubation, plates were washed in PBS and fixed in
3.7% formaldehyde in PBS. In initial experiments, we stained the
microglia with tomato lectin for 45 mins and stained all nuclei
with DAPI. Ten fluorescence micrographs of each culture were
taken with a Zeiss Axiovert-based imaging system. Counting of the
cells showed that the number of the microglia did not change over
the observation period of 3 days. Therefore in subsequent
experiments the cells were stained with SRB as described for the
colony formation assay. After drying, the plates were de-stained
with 500 mL of 10 mM Tris base (Sigma). Eluted SRB was
measured by absorbance at 490 nm. To determine the cell
growth, the OD at day 1 was subtracted from the OD at day 3.
Animal Experiments
First, 8 week old male C57BL/6J mice were inoculated in the
right caudate putamen with GL261 cells. Briefly, animals were
placed in a stereotactic frame after pre-anesthesia exposure in a
box of 5% isoflurane. Deep anesthesia was maintained on the
frame at approximately 2% isoflurane and 2% O2. A burr hole
was drilled 1 mm anterior and 2.5 mm to the right of the bregma.
With the aid of the stereotactic frame, GL261 cells (26104 cells
suspended in 1 mL) were injected with a Hamilton syringe at a
depth of 3 mm over a one minute time period. Subsequently, the
syringe was left in place for 1 minute to prevent reflux.
Seven days after implantation of the GL261 cells, an osmotic
pump (Alzet, Durect) filled with either 0.42 mg/ml solution of
semapimod or vehicle was implanted in a subcutaneous pocket on
the dorsal flank of the animal. A catheter with attached cannula
delivered the drug intracranially over a period of 2 weeks, at a
steady rate of 0.25 ml/h, which is equivalent to a dose of 6 mg/kg/
day, assuming no blood-brain barrier permeability of the drug.
Starting one day after pump implantation, animals were given
2 Gy whole brain irradiation every other day over a period of 10
days (10 Gy total). Animals that lost greater than 20% in body
Glioblastoma Radio-Sensitization by Semapimod
PLOS ONE | www.plosone.org 2 May 2014 | Volume 9 | Issue 5 | e95885
weight or displayed paralysis and/or lack of grooming, were
deemed moribund and euthanized immediately.
Brains from tumor-bearing mice were frozen on dry ice and
stored at 280uC until processing. The brain was sliced using a
cryostat at 220uC at a thickness of 40 mm (for tumor sizing) or
8 mm for immunohistochemistry. Slices were placed on pre-coated
poly-l-lysine slides (Superfrost, Fisher) and fixed in 3.7% formal-
dehyde in PBS. Sections were stained with Harris-modified
haematoxilin solution. Activated microglia were visualized with
an Iba1 antibody (Wako). Tumor cell invasion was determined by
counting the number of Ki67 (Millipore) positive nuclei located
beyond the tumor border. The border was outlined by determin-
ing where the bulk of the tumor material was found by Ki67
staining. Tumor size was determined as the area of the largest
cross section of the tumor, multiplied by the depth of the tumor.
The cell density of the tumor was calculated by counting the
total number of cells in 10 fields taken over different sections and
multiplying the tumor area by the thickness of the slice (8 mm) to
obtain total number of cells in a tumor section. This was then
divided by the volume of the tumor section to obtain the number
of cells per unit volume. To obtain the total number of cells in a
tumor, the cell density was multiplied by the calculated volume of
the tumor.
TUNEL Assay
Frozen brains were sectioned and tested for apoptosis using the
TACS 2 TdT-DAB in Situ Apoptosis Detection Kit from Trevigen
following the manufacturer’s recommendations. Slices were
imaged with the Zeiss Axiovert 200 M microscope and a 406
objective. Images were analyzed with the Axiovision program. For
each tumor, 20 to 60 fields were analyzed.
Statistics
For the experiments determining the therapeutic benefit of
semapimod in animals, a chi-squared test with 3 degrees of
freedom was used. For all other experiments a two-tailed Student’s
t-test was used.
Results
Semapimod inhibits microglia-stimulated glioblastoma
cell invasion
In order to examine the effect of microglia on the malignant
properties of glioblastoma cells, we used GL261 murine glioblas-
toma cells and syngeneic microglia isolated from C57Bl/6 mice, a
model system that has been extensively used to study the
reciprocal interaction between glioblastoma cells and microglia
[11,12,19].
A defining feature of malignant glioblastoma is the diffuse
invasion of tumor cells into the surrounding parenchyma and
microglia have been shown to strongly promote this activity
[11,19–22]. To determine the effect of microglia on the invasive
properties of glioblastoma cells, we designed a novel 3-dimensional
microglia–glioblastoma co-culture assay that provides a better
approximation of the in vivo setting than a 2-dimensional
configuration. Fluorescently labeled cells were embedded in
reconstituted extracellular matrix (BME) in the absence of added
serum at a ratio of 3:1 glioblastoma cells to microglia and
subsequently placed in transwells provided with an 8 mm pore
filter. Using this assay, we observed that microglia stimulate
GL261 invasion up to 5 fold and that semapimod interferes with
this effect with an IC50 of less than 50 nM (Fig. 1A), similar to the
IC50 of semapimod in inflammatory cytokine release from
macrophages [14]. Importantly, semapimod, even at a concen-
tration of 10 mM, does not affect serum-stimulated GL261
invasion, underlining the selectivity of semapimod for cells from
the monocytic lineage (Fig. 1B).
Figure 1. Semapimod inhibits microglia-stimulated glioblasto-
ma invasion in vitro. (A) Semapimod inhibits microglia-stimulated
glioblastoma cell invasion. GL261 cells were embedded in basement
membrane extract (BME) with or without microglia in the presence of
the indicated concentrations of semapimod, layered in the transwell
and incubated for 48 h. The total number of invading GL261 cells was
determined and normalized to that of GL261 cells in monoculture. Data
shown represent the average +/2 SEM of 3 independent experiments,
performed in duplicate. (B) Semapimod does not affect serum-
stimulated glioblastoma cell invasion. GL261 cells embedded in BME
in the presence of the indicated concentration of semapimod, were
layered in the transwell and incubated for 48 h. Serum (10% FBS) was
added to the bottom well. The total number of invading GL261 cells
was determined and normalized to that of GL261 cells in the absence of
drug. Data shown represent the average +/2 SEM of 3 independent
experiments. (C) Semapimod inhibits glioblastoma cell-stimulated
microglia invasion. Glioblastoma cells were plated in the bottom well
and microglia were embedded in BME in the presence or absence of
200 nM semapimod, layered in the transwell and incubated for 48 h.
The total number of invading microglia cells was determined. Data
shown represent the average +/2 SEM of 3 independent experiments.
*: p,0.05, **: p,0.01 student’s 2 tailed t-test.
doi:10.1371/journal.pone.0095885.g001
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Semapimod inhibits glioblastoma-induced microglia
invasion in vitro
Microglia extensively infiltrate glial tumors [6,8,9]. To examine
whether semapimod can also inhibit migration of microglia
towards glioblastoma cells, we established an in vitro transwell
invasion assay by measuring the number of microglia that invade
through a 3-dimensional extracellular matrix toward glioblastoma
cells. We observed that the presence of GL261 cells in the bottom
well strongly stimulates microglia invasion, by approximately 12
fold (Fig. 1C). This stimulatory effect is abolished by semapimod,
with an IC50 of approximately 60 nM.
Semapimod inhibits microglia-stimulated glioblastoma
cell survival
A critical problem of malignant glioblastoma is its strong
resistance to ionizing radiation (IR) and other therapeutic
modalities [23]. The role of microglia in glioblastoma cell survival
has not been studied thus far. We therefore examined whether
microglia can enhance the survival of GL261 cells after IR and
whether semapimod interferes with this function. GL261 cells
were plated either in the presence or absence of microglia with or
without semapimod (200 nM) for 2 days, followed by radiation
treatment (3 Gy). Two days later, glioblastoma cell viability was
assayed using a standard colony formation assay. We observed
that co-culturing GL261 cells with microglia in the absence of
radiation slightly, but significantly, stimulates their survival and
that semapimod abolishes this (Fig. 2A). In the presence of
radiation, the stimulatory effect of microglia on glioblastoma cell
survival is more marked (50%) and this effect is also abolished by
semapimod (Fig. 2B). In line with the selectivity of semapimod for
cells from the monocytic lineage, semapimod does not affect the
survival potential of glioblastoma cell monocultures. Thus, taken
together, these data indicate that semapimod inhibits microglia-
stimulated glioblastoma cell survival by modulating the activation
state of the microglia.
Semapimod does not affect microglia-stimulated
glioblastoma cell proliferation
Microglia have been shown to slightly stimulate glioblastoma
cell proliferation and therefore we also wanted to examine whether
semapimod inhibits this effect. Fig. 3 shows that microglia
stimulate GL261 cell proliferation in a fashion that depends on
the microglia-glioblastoma cell ratio. However, semapimod
(200 nM) does not affect the microglia-stimulated glioblastoma
cell proliferation.
Semapimod strongly inhibits tumor cell invasion in vivo
To evaluate the effect of semapimod on the malignant behavior
of glioblastoma in vivo, we used orthotopic implantation of GL261
cells into syngeneic C57Bl/6 mice. This model displays all the
pathological hallmarks of glioblastoma and is often used for
examining the role of microglia in glioblastomagenesis and for pre-
clinical evaluation of immunomodulatory therapies [11,12,19,24].
In order to identify an effective dose of semapimod, we
performed pilot studies and chose the minimal concentration that
maximally inhibited tumor invasiveness one week after start of
treatment. Animals were inoculated with 26104 GL261 cells into
the right caudate putamen. To deliver semapimod, we used an
osmotic pump that was implanted subcutaneously in the dorsal
flank of the animal and fed a transcranial cannula that was
inserted into the tumor. In order to mimic a therapeutic setting,
tumors were allowed to develop for 1 week before the onset of
Figure 2. Semapimod removes microglia-induced radioprotec-
tion on GL261 in vitro. GL261 cells were cultured in the presence or
absence of microglia and in the presence or absence of 200 nM of
semapimod, followed by a colony formation assay. (A) Colony formation
assay of GL261 after treatment with microglia and semapimod. (B)
Determination of survival of GL261 after treatment with 3 Gy
irradiation, microglia and semapimod. Data shown represent the
average +/2 SEM of 3 independent experiments. *: p,0.05 student’s
2 tailed t-test.
doi:10.1371/journal.pone.0095885.g002
Figure 3. Semapimod does not affect microglia-stimulated
growth of glioblastoma cells in vitro. GL261 cells were cultured in
the presence or absence of microglia at the indicated ratio’s, in the
presence and absence of 200 nM semapimod. Cell growth over a period
of 3 days was determined using the SRB method. Data shown represent
the average +/2 SEM of 3 independent experiments. *: p,0.05, **: p,
0.01 student’s 2 tailed t-test.
doi:10.1371/journal.pone.0095885.g003
Glioblastoma Radio-Sensitization by Semapimod
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treatment. To score tumor cell invasion, brain sections were
probed for the presence of proliferative antigen Ki67. In line with
our in vitro observations, semapimod, at a dose that is equivalent to
6 mg/kg/day, strongly inhibited tumor invasion. Whereas control
tumors display diffuse edges and extensive tumor cell invasion into
the surrounding parenchyma, semapimod-treated tumors have a
sharply demarcated border (Fig. 4A). Quantification of the
invading tumor cells revealed that semapimod inhibits tumor cell
invasion by more than 75% (Fig. 4B).
As our in vitro observations showed that semapimod strongly
inhibits invasion of microglia toward GL261 cells, we also
examined tumor sections for the infiltration of microglia using
Iba1 staining (Fig. 4C). No significant difference in the number of
microglia per tumor area could be detected, however (Fig. 4D).
The most likely interpretation for this finding is that semapimod
treatment was started 7 days after the implantation of the tumor
cells, a time at which microglia infiltration already has occurred
[25].
As semapimod does not affect GL261 cell proliferation in vitro,
we were surprised by the finding that semapimod treatment causes
a robust inhibition of tumor size, two weeks after tumor cell
inoculation (Fig. 5A). Interestingly, the treated tumors also display
a small but significant increase in tumor cell density (Fig. 5B),
possibly caused by the strong inhibitory effect of semapimod on
tumor cell invasion. Still, the estimated total number of cells in
semapimod-treated tumors is significantly less than that in control
tumors, indicating that semapimod indeed diminishes the prolif-
eration potential of the tumor cells in vivo (Fig. 5C). The
discrepancy between the in vitro and the in vivo tumor cell
proliferation data may be due to the fact that the in vivo
observations reflect the cumulative effect of many cell divisions,
thereby possibly amplifying small differences in cell proliferation
that are not detectable in the in vitro experiments.
Semapimod strongly enhances the therapeutic efficacy
of ionizing radiation in a syngeneic orthotopic mouse
model of glioblastoma
To determine the effect of semapimod on the survival of
glioblastoma-bearing mice and to examine the effect of semapi-
mod on radiation resistance in vivo, we randomized 4 groups of
animals to receive semapimod or diluent in the absence or
presence of 10 Gy fractionated whole brain irradiation. We
observed that in the absence of radiation, semapimod does not
significantly prolong survival (median survival of 22 days for
semapimod-treated animals versus 20 days for controls) (Fig. 6).
However, whereas radiation alone increased median survival by
12 days, most of the irradiated animals that were treated with
semapimod survived at least 40 days beyond the median survival
time of control animals and had no detectable tumors as judged by
histological analysis (data not shown). These observations indicate
that semapimod strongly sensitizes GL261 tumors to radiation.
To examine whether semapimod promotes radiotherapy-
induced glioma cell death in vivo, we performed TUNEL staining
on sections from control and treated tumors. Treatment with
semapimod approximately doubled the percentage of apoptotic
tumor cells in irradiated but not in non-irradiated animals (Fig. 7),
strongly supporting the hypothesis that semapimod acts as a
radiosensitizer in glioma tumors in vivo.
Discussion
In this paper, we show that the immunomodulatory drug
semapimod markedly enhances the survival of glioblastoma-
bearing mice in conjunction with radiation therapy, but not as
monotherapy. In addition, our in vitro observations show that
semapimod inhibits the survival of irradiated glioblastoma cells in
the presence, but not in the absence, of microglia. Taken together
therefore, our results strongly suggest that semapimod sensitizes
glioblastoma tumors to ionizing radiation by targeting microglia.
The notion that semapimod targets microglia, but not
glioblastoma cells, is in line with previous data showing that
semapimod is selective for cells derived from the monocytic
lineage, i.e. microglia, macrophages and dendritic cells, but not T
cells [15,26]. We note that gliomas also are infiltrated by
peripheral macrophages [25], which also may promote therapeu-
tic resistance. Thus, the inhibitory effect of semapimod on the
Figure 4. Semapimod inhibits glioblastoma cell invasion in
vivo. GL261 cells were orthotopically implanted into C57Bl/6 mice.
Starting 7 days after cell inoculation, the mice were treated
intracranially for 1 week with semapimod, delivered via an osmotic
pump. (A) Micrographs of tumor sections illustrating inhibition of GL261
cell invasion by semapimod. GL261 cells were visualized using Ki67
staining. The tumor borders are outlined. Scale bar represents 200 mm.
(B) Quantification of the number of invaded GL261 cells normalized to
the length of the tumor border (expressed in mm). Data shown
represent the average +/2 SEM of 5 different tumors. **: p,0.01
student’s 2 tailed t-test. (C) Micrographs illustrating infiltration of
microglia into GL261 tumors. Activated microglia were visualized using
Iba1 staining. (D) Quantification of Iba1+ microglia infiltrated into the
tumor. Scale bar represents 100 mm. Data shown represent the average
+/2 SEM of 5 different tumors.
doi:10.1371/journal.pone.0095885.g004
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activation status of infiltrating macrophages may also contribute to
the therapeutic effect of semapimod.
The mechanism of action of semapimod remains to be
elucidated. The only known molecular target of semapimod to
date is c-Raf [27]. However, we found that ERK activation in
microglia that are stimulated by GL261-conditioned medium is
not inhibited by semapimod (data not shown), suggesting that this
proposed mechanism is not relevant for our observations. Exactly
how semapimod modulates microglial function is currently under
investigation in our laboratory.
We note that semapimod has been extensively used as an anti-
inflammatory agent [27,28]. Thus, our results that semapimod
sensitizes tumors to radiation therapy may seem paradoxical, as
the immune system, in general, is thought to counteract tumor
formation. We note, however, that there is now mounting
evidence in the literature that targeting microglia/macrophages
may be of therapeutic benefit in the treatment of glioblastoma
[5,6,7,11,12,22,25,29] and other malignancies [30].
Hitherto, the role of microglia in the malignant behavior of
glioblastoma cells has largely focused on the invasiveness of the
tumor cells [5,6] and the effect of microglia on the survival
properties of glioblastoma cells has not been investigated. In this
paper, we report that microglia exert a small, but significant,
stimulatory effect on the survival of glioblastoma cells that are
challenged by ionizing radiation and that semapimod inhibits this
effect. In line with this result, we find that semapimod treatment
increases the number of apoptotic tumor cells induced by ionizing
radiation in vivo and markedly extends the survival of glioblastoma-
Figure 5. Semapimod inhibits tumor growth in vivo. GL261 cells were implanted and mice were treated as described in Fig. 4. (A)
Quantification of tumor volume. Data shown represent the average +/2 SEM of 5 different tumors. (B) Quantification of tumor cell density. Data
shown represent the average +/2 SEM of 5 different tumors. (C) Quantification of total tumor cell number. Data shown represent the average +/2
SEM of 5 different tumors. *: p,0.05 student’s 2 tailed t-test.
doi:10.1371/journal.pone.0095885.g005
Figure 6. Semapimod increases survival of glioblastoma-
bearing mice in conjunction with ionizing radiation. C57Bl/6
mice were injected orthotopically with GL261 cells. Starting 7 days after
cell inoculation, the mice were treated intracranially for 2 weeks with
semapimod, delivered via an osmotic pump. Starting on day 8, animals
were given 2 Gy whole brain irradiation every other day over a period of
10 days (10 Gy total). *: p,0.05. Chi square test, with 3 degrees of
freedom.
doi:10.1371/journal.pone.0095885.g006
Figure 7. Semapimod increases apoptosis induced by radiation
in vivo. GL261 tumors were generated in mice and treatments were
carried out as described in Fig. 6, except that the total radiation was
8 Gy. The mice were euthanized the day after the last radiation
treatment. Frozen brain sections were analyzed for apoptosis using
TUNEL staining as described in Materials and Methods. (A) Micrographs
of tumor sections illustrating TUNEL staining. (B) Quantification of
TUNEL staining. The percentage of apoptotic cells was calculated using
20–60 micrographs per tumor section. Data shown represent the
average +/2 SEM of 3–4 different tumors. *: p,0.05 student’s 2 tailed t-
test.
doi:10.1371/journal.pone.0095885.g007
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bearing animals that are treated with radiation. The relatively
large effect size of semapimod treatment observed in vivo may be
explained by the use of a fractionated radiation regimen (5 doses of
2 Gy, every other day), which is expected to magnify the survival
benefit seen in the single dose of irradiation in the in vitro setting.
The striking enhancement by semapimod of the therapeutic
effect of ionizing radiation in glioblastoma-bearing mice is in line
with the radiosensitization observed by depleting macrophages in
a subcutaneous melanoma model [31] and the marked enhance-
ment of the inhibitory effect of paclitaxel on mammary tumor
pulmonary metastasis caused by a CSF-1R inhibitor that blocks
macrophage recruitment to the tumor [32]. Notably, in all these
cases, targeting the tumor-associated microglia/macrophage
compartment on its own showed little or no therapeutic benefit.
These observations strongly suggest that the microglia/macro-
phage compartment plays a critical role in therapeutic resistance
and that targeting this compartment in combination with other
therapeutic modalities is likely to be of significant clinical benefit.
We found that semapimod has a marked inhibitory effect on
glioblastoma tumor cell invasion both in vitro and in vivo. These
observations are in line with previous reports that have demon-
strated that interference with the function of microglia or depletion
of the microglial compartment has a strong inhibitory effect on
glioblastoma cell invasion [11,19]. Interestingly however, the
marked inhibition in tumor invasiveness caused by semapimod is
not accompanied by a significant increase in survival of
glioblastoma-bearing mice. This observation suggests that blocking
invasion on its own may have little therapeutic benefit, at least in
the setting that we have explored. However, in other preclinical
settings, inhibiting invasion could yield therapeutic benefit.
Possible scenarios include the implementation of a tumor resection
model [33], which better mimics current therapeutic approaches
in the clinic, or combined treatment with bevacizumab, which has
been shown to enhance the invasive behavior of glioblastoma
tumors [34,35].
An attractive feature of semapimod is that it is an investigational
drug that already has been tested in several clinical trials
[17,36,37]. Importantly, semapimod was shown to be very well
tolerated in humans and displays a good safety profile. Thus, our
observations suggest the utility of repositioning semapimod as an
immunomodulator for the treatment of glioblastoma, as up-front
adjuvant to standard therapy, concurrent with radiation and
temozolomide chemotherapy [1].
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